Susvimo (ranibizumab port delivery system) / Roche - LARVOL DELTA

Structural Updates to the Implant and Refill Needle of the Port Delivery Platform. (PubMed, Transl Vis Sci Technol) - "The purpose of this study was to report the impact of component-level changes and manufacturing process improvements on septum durability in the ocular implant of the Port Delivery Platform (PD-P), more commonly known as the Port Delivery System with ranibizumab (PDS) with its current formulation...Structural updates to the PD-P implant and refill needle have met and exceeded performance specifications, mitigating the risk of future septum dislodgement in the updated product. Structural updates to the PD-P implant and refill needle resulted in the ability to withstand the equivalent of over 50 years of simulated use without septum dislodgement and should improve the longevity of the device in clinical use."

Journal

Volumetric analysis of retinal fluids in Archway phase 3 trial of the Port Delivery System with ranibizumab (PDS) in patients with nAMD (ARVO 2025) - P3 | "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • P3 data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Strategies for Minimizing Early and Late Complications of the Port Delivery System (ARVO 2025) - "Describe the big picture and the implications of your findings, not the study itself and the associated details. Frequent intraocular injections in diabetes and wet macular degeneration eyes can be reduced to twice yearly with a newly designed implant which delivers Lucentis over extended period of time."

Age-related Macular Degeneration • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Real-World Efficacy and Safety of the Ranibizumab Port-Delivery System in Neovascular AMD: First Time Two-Year Results of the SUMMIT Study (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Pigment Epithelial Detachment Thickness Fluctuations in the Archway Trial of the Port Delivery System With Ranibizumab (ARVO 2025) - P3 | "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Retinal fluid and thickness fluctuations in patients with diabetic macular edema: results from the Pagoda trial of Port Delivery System with Ranibizumab (PDS) (ARVO 2025) - P3 | "In results from the first 2 years of the study, the PDS helped to control fluid buildup in the eye and changes to the thickness of the retina as effectively as monthly ranibizumab injections, with similar improvements in vision. These results suggest that the PDS could benefit patients without the need for monthly eye injections."

Clinical • Diabetic Macular Edema • Ophthalmology

Sustained suppression of aqueous humor free vascular endothelial growth factor following continuous delivery via the Port Delivery System with ranibizumab in the Pagoda and Pavilion trials (ARVO 2025) - P3 | "Researchers collected eye fluid samples at different times to test VEGF levels in treated eyes. The VEGF levels in the eyes with the PDS remained low throughout treatment with PDS, including up to 9 months after refill, and were similar to levels in eyes treated with monthly eye injections."

Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders • VEGFA

Impact of Port Delivery System with ranibizumab (PDS) treatment in study eyes vs anti-VEGF injections in fellow eyes on efficacy and safety outcomes in patients with bilateral diabetic macular edema (DME) in the Pagoda trial (ARVO 2025) - P3 | "However, the PDS eyes showed better control of disease activity, including the prevention of disease worsening. Side effects affecting the eye were similar in both the eyes treated with the PDS and those receiving anti-VEGF injections."

Clinical • Diabetic Macular Edema • Diabetic Retinopathy • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial. (PubMed, JAMA Ophthalmol) - P3 | "These findings should be balanced with the transient, postoperative decrease in BCVA 4 through 12 weeks after implantation and the need for longer-term BCVA and safety outcomes. ClinicalTrials.gov Identifier: NCT04503551."

Clinical • Journal • Cataract • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Hematological Disorders • Macular Edema • Metabolic Disorders • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. (PubMed, JAMA Ophthalmol) - P3 | "Continuous ranibizumab, 100 mg/mL, via PDS was approved in the US for patients with DME in February 2025 and provides effective, durable, and generally well-tolerated treatment for DME with retreatment every 6 months through at least 64 weeks. ClinicalTrials.gov Identifier: NCT04108156."

Clinical • Journal • Diabetic Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Macular Atrophy-Related Observations in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial. (PubMed, Ophthalmol Retina) - "In the Archway trial, which compared PDS Q24W with monthly ranibizumab injections for nAMD treatment over 2 years, prevalence and incidence of MA were similar between arms over the study duration. In eyes without baseline MA, PDS-treated eyes had less MA area by 3.4 mm2, a potentially clinically meaningful (although not statistically significant) difference. The results of this prespecified exploratory analysis suggest that PDS treatment is not associated with higher incidence or progression of MA when compared with monthly injections of ranibizumab. In eyes without baseline MA, the progression of atrophy area was 4 times less in PDS-treated eyes. Additional studies could further elucidate this observation."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Sightspire: A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD (clinicaltrials.gov) - P3 | N=250 | Not yet recruiting | Sponsor: Hoffmann-La Roche

New P3 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Pagoda: A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME (clinicaltrials.gov) - P3 | N=634 | Recruiting | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Recruiting | Trial primary completion date: Sep 2022 ➔ Nov 2026

Enrollment open • Trial primary completion date • Diabetic Macular Edema • Ophthalmology

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness (Businesswire) - "Genentech...announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss in adults with diabetes, affecting more than 29 million adults worldwide. Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections. Susvimo is now available to U.S. retina specialists and their patients with DME....The FDA decision was based on positive one-year results from the Phase III Pagoda study..."

FDA approval • Launch US • Diabetic Macular Edema

Biodegradable polymeric microsphere formulations of full-length anti-VEGF antibody bevacizumab for sustained intraocular delivery. (PubMed, Drug Deliv Transl Res) - "In 2021, the FDA approved an innovative port delivery system of ranibizumab (Susvimo®) that can be implanted intravitreally to slowly release the active ingredient anti-VEGF antibody and reduce injection frequency to once every 6 months. Using the traditional double emulsion fabrication method with PCL polymer, we could produce microspheres that encapsulate bevacizumab antibody and demonstrate the release of biologically active therapeutic agent for up to 60 days. This novel approach could lead to significant advancements in our field and potentially open new avenues for future research."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

PAVILION: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (clinicaltrials.gov) - P3 | N=174 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: May 2024 ➔ Jun 2025

Trial completion date • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

VOYAGER: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (clinicaltrials.gov) - P=N/A | N=6000 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Dec 2027 ➔ Sep 2027

Real-world evidence • Trial completion date • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Transscleral Pars Plana Choroid Ablation Using the Iridex Laser System Yields Improvements for Surgical Insertion of the Port Delivery Implant in a Minipig Model. (PubMed, Retina) - "This Göttingen minipig model demonstrated a novel application of Iridex laser for transscleral pars plana ablation that streamlines the PDS implantation surgery."

Journal • Hematological Disorders • Ophthalmology • Retinal Disorders

Drugs for age-related macular degeneration. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

The Safety of Recently Approved Therapeutics in Age-Related Macular Degeneration. (PubMed, Int Ophthalmol Clin) - "In nAMD, the newest agents approved by the FDA are brolucizumab (Novartis Pharmaceuticals, Basel, Switzerland), faricimab (F. Hoffman-La Roche, Basel, Switzerland), aflibercept 8 mg (Regeneron Pharmaceuticals, Tarrytown, NY, USA), and a new device in the port delivery system with ranibizumab (Genentech, San Francisco, CA, USA). The first agents FDA-approved for GA secondary to neAMD are pegcetacoplan (Apellis Pharmaceuticals, Waltham, MA, USA) and avacincaptad pegol (Iveric Bio, Parsippany, NJ, USA)...Real-world data, as demonstrated in both registrational studies along with retrospective chart review studies, has shown to be an important factor in the implementation of newer drugs, along with the treatment decisions that physicians choose to make regarding their dosing and follow-up. This review article discusses the safety of the most recently approved FDA as seen in both clinical trials and real-world studies."

Journal • Review • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Home OCT and Sustained Delivery Approaches, a Perfect Marriage: Home OCT and Sustained Drug Delivery: A Perfect Marriage. (PubMed, Am J Ophthalmol) - "The combined use of sustained drug delivery and validated remote monitoring portends a significant change in the current nAMD treatment landscape and has the potential to reduce the injection and monitoring burden faced by patients while optimizing patient outcomes."

Journal • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Faricimab Treatment of Polypoidal Choroidal Vasculopathy Resistant to Intravitreal Ranibizumab Injections and Ranibizumab Port Delivery (Susvimo). (PubMed, J Vitreoretin Dis) - " This case shows the potential therapeutic benefits of targeting angiopoietin-2 in addition to vascular endothelial growth factor to treat PCV refractory to ranibizumab. Faricimab may provide an alternative to therapy with ranibizumab and verteporfin photodynamic therapy for the treatment of PCV."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Refillable Drug Reservoirs for Retinal Vascular Diseases. (PubMed, Am J Ophthalmol) - "Although devices with refillable reservoirs have increased challenges related to their inherent complexity, the potential for improved patient outcomes merit further development of this technology."

Journal

Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System With Ranibizumab vs Monthly Ranibizumab Injections. (PubMed, Ophthalmol Retina) - P3 | "PDS Q24W maintained BCVA to 96 weeks regardless of SRF/IRF, central SRF, central IRF, or CST fluctuations, comparable with monthly ranibizumab, thus supporting the use of the PDS in stabilizing retinal anatomy without the need for monthly treatment in patients with nAMD."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Early SUSVIMO in Neovascular Age-Related Macular Degeneration: Real Word Case Report and Clinical Implications. (PubMed, Int Med Case Rep J) - "Although effective, real-world management of neovascular age-related macular degeneration is associated with an extensive treatment burden that can compromise treatment adherence. Herein, we describe how the port delivery system (PDS; SUSVIMO) - a refillable ocular implant that can continuously deliver a novel formulation of ranibizumab with refills possible at six months or longer - is a viable early therapy that mitigates the treatment burden of intravitreal injections."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration